Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update

<p>Top Line Results from CLEAR MIND Alzheimer’s disease Trial Affirm Safety Profile of Lomecel-B™ and Provide Efficacy Signal; Full Study Data Remains on Track to Share in Coming Weeks Long-term Survival Data from ELPIS 1 Trial to be Presented at the 2023 Scientific Sessions of the American Heart Association $4 Million in Equity Financing Secured […]</p>
<p>The post <a href="https://forextv.com/top-news/longeveron-reports-third-quarter-2023-results-and-provides-corporate-update/">Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>